Catalyst Pharmaceuticals, Inc. (CPRX) filed an 8-K announcing the completion of an acquisition or disposition of assets. The filing does not provide specific terms but incorporates disclosures from other sections of the report. This is a routine announcement of a completed transaction.

View Full Filing (SEC EDGAR)

2026-07-08

Catalyst Pharmaceuticals (ticker: CPRX) filed an 8-K on July 8, 2026, disclosing that all seven of its directors, including CEO Patrick J. McEnany, will resign effective at the close of its merger with Italy's Angelini Pharma. The resignations are a condition of the merger agreement and are not related to any disputes with the company.

View Full Filing (SEC EDGAR)

2026-06-30

No AI summary for this filing type

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding CATALYST PHARMACEUTICALS INC (CPRX)?

Major stakeholders currently include BlackRock, Inc. ($464.9M), State Street CORP ($169.9M), Vanguard Capital Management LLC ($126.8M). Based on the latest 13F filings, there are a total of 379 tracked investment funds and institutions maintaining positions in CPRX.

What is the overall institutional sentiment toward CPRX recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $166.9M, driven by 193 managers accumulating shares while 161 reduced their exposure.

Which institutions have been selling or reducing their CPRX positions?

In the latest period, 121 funds trimmed their holdings, and 40 managers completely exited their positions. The aggregate reported sell value was $982.2M.

Are there any notable investors adding CPRX to their portfolios?

Yes, buying activity remains notable. 45 institutions opened new positions in {ticker}, and 148 existing holders added to their shares. The total reported buy value for the quarter amounted to $1.5B.